# Ascitic Fluid Cytology Provides Diagnostic Clues in a Case of Gastric Metastasis from Invasive Lobular Carcinoma of the Breast

**Authors:** Takashi Matsutani, Noriyuki Nishiwaki, Tomokazu Kakishita, Takaya Kobatake, Koji Ohta, Shinji Hato

PMC · DOI: 10.70352/scrj.cr.25-0515 · Surgical Case Reports · 2026-03-06

## TL;DR

A case study shows how analyzing ascitic fluid helped diagnose gastric metastasis from a prior breast cancer, highlighting the importance of cytology in such ambiguous cases.

## Contribution

Demonstrates the diagnostic utility of ascitic fluid cytology in identifying metastatic breast cancer in the stomach.

## Key findings

- Cytological examination of ascites revealed tumor cells positive for GATA3 and estrogen receptor, and negative for E-cadherin.
- The case highlights the difficulty in differentiating primary gastric cancer from metastatic breast cancer.
- Ascitic fluid cytology proved essential for accurate diagnosis and avoiding unnecessary treatment.

## Abstract

Breast cancer metastasis to the gastrointestinal tract is rare, and invasive lobular carcinoma (ILC) shows a higher propensity for dissemination than invasive ductal carcinoma. Accurate diagnosis is often challenging because of nonspecific clinical and pathological findings.

A 53-year-old woman presented to our hospital with a diagnosis of gastric cancer discovered during gastrointestinal cancer screening. Fourteen years earlier, she had undergone a right mastectomy for ILC and subsequently received treatment for local recurrence and bone metastasis. The gastric lesion was initially diagnosed as primary gastric cancer, and adjuvant chemotherapy was administered after gastrectomy. However, postoperative ascites gradually worsened. Five years after gastrectomy, cytological examination of the ascites revealed tumor cells positive for GATA3 and estrogen receptor, and negative for E-cadherin, leading to a diagnosis of peritoneal metastasis from breast cancer.

ILC is characterized by a loss of E-cadherin and diffuse metastatic patterns, including peritoneal and gastric involvement. This case highlights the diagnostic difficulty of differentiating primary gastric cancer from metastatic breast cancer. Although tumor markers and imaging suggested gastric cancer recurrence, cytological examination revealed otherwise. Ascitic fluid cytology is essential for definitive diagnosis, emphasizing its diagnostic value for patients with ambiguous gastric lesions and a history of breast cancer.

Metastasis should be considered in the differential diagnosis of patients with prior breast cancer presenting with gastric lesions. Ascitic fluid cytology can be a useful adjunct for an accurate diagnosis, guiding appropriate treatment, and avoiding unnecessary interventions.

## Linked entities

- **Proteins:** GATA3 (GATA binding protein 3), shg (shotgun)
- **Diseases:** gastric cancer (MONDO:0001056), invasive lobular carcinoma (MONDO:0005051), breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, CEACAM3 (CEA cell adhesion molecule 3) [NCBI Gene 1084] {aka CD66D, CEA, CGM1, CGM1a, W264, W282}, GATA3 (GATA binding protein 3) [NCBI Gene 2625] {aka HDR, HDRS}
- **Diseases:** gastrointestinal cancer (MESH:D005770), invasive ductal carcinoma (MESH:D044584), gastric (MESH:D013272), lymph node metastasis (MESH:D008207), gastric bleeding (MESH:D013274), Breast cancer (MESH:D001943), depressed lesion (MESH:D003866), gastrointestinal infiltration (MESH:D017254), Metastatic (MESH:D000092182), PRESENTATION (MESH:D001946), ILC (MESH:D018275), Peritoneal carcinomatosis (MESH:D010534), peritoneal dissemination (MESH:D010538), adenocarcinoma (MESH:D000230), carcinoma (MESH:D009369), Breast (MESH:D061325), mastectomy (MESH:D000072656), ascites (MESH:D001201), disease (MESH:D004194), Gastric Metastasis (MESH:D009362)
- **Chemicals:** oxaliplatin (MESH:D000077150), bevacizumab (MESH:D000068258), cyclophosphamide (MESH:D003520), eosin (MESH:D004801), nivolumab (MESH:D000077594), folinic acid (MESH:D002955), fluorouracil (MESH:D005472), FDG (MESH:D019788), paclitaxel (MESH:D017239), denosumab (MESH:D000069448), hematoxylin (MESH:D006416), Papanicolaou (-), epirubicin (MESH:D015251), FOLFOX (MESH:C410216), HE (MESH:D006371)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967855/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12967855/full.md

## References

22 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967855/full.md

---
Source: https://tomesphere.com/paper/PMC12967855